Supplemental Figure 3 from Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
Year: 2023
Type: supplementary-materials
Abstract: pre-EGFR-TKI TMB by TP53 co-mutation and incidence of TP53 co-mutation by tertile (low/intermediate vs high)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361932043